2-isobutyl-tetrahydro-thiophene | 5143-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 硫杂环戊烷
• 英文名称: 2-isobutyl-tetrahydro-thiophene
• 英文别名: 2-Isobutyl-tetrahydro-thiophen；2-Isobutyl-thiolane；2-(2-methylpropyl)thiolane
• CAS: 5143-20-4
• 化学式: C₈H₁₆S
• 分子量: 144.281
• InChiKey: VNAMKUWAEAHCJL-UHFFFAOYSA-N

物化性质

• 保留指数：
  1080

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium sulfide 、 乙醇 作用下， 生成 2-isobutyl-tetrahydro-thiophene
  参考文献：
  名称：

  Obolenzew; Bucharow, 1957, p. 9,14, 17

  摘要：

  DOI：

文献信息

• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070099874A1

  公开（公告）日：2007-05-03

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及用于治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖化蛋白诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗由平滑肌增殖所特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。
• Indoleamine 2,3-dioxygenase inhibitor and application
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US11046679B2

  公开（公告）日：2021-06-29

  The present invention belongs to the field of medical technology. Particularly, the present invention relates to a compound shown in formula (I), a pharmaceutically acceptable salt thereof, and a stereoisomer of the same. X, Y, Z, R1, R2, R3, R1a, R2a, m, and n are as defined in the specification. The present invention also relates to pharmaceutical preparations and pharmaceutical compositions of these compounds and a use thereof in preparing a drug for treating a related disease mediated by abnormal indoleamine 2,3-dioxygenase (IDO).

  本发明属于医疗技术领域。特别是，本发明涉及一种式（I）所示的化合物、其药学上可接受的盐及其立体异构体。X、Y、Z、R1、R2、R3、R1a、R2a、m 和 n 如说明书中所定义。本发明还涉及这些化合物的药物制剂和药物组合物及其在制备治疗由异常吲哚胺 2，3-二氧 化酶（IDO）介导的相关疾病的药物中的用途。
• Onesta; Ferretti, Gazzetta Chimica Italiana, 1955, vol. 85, p. 1185,1192
  作者：Onesta、Ferretti

  DOI：——

  日期：——
• MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
  申请人：Tranzyme Pharma, Inc.

  公开号：EP1773869B9

  公开（公告）日：2013-01-23
• INHIBITORS OF PROTEIN KINASES
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20200239458A1

  公开（公告）日：2020-07-30

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.